title: Tardive dyskinesia and associated cognitive disorders: a convergent neuropsychological and neurophysiological approach.
abstract: This study sought to assess whether tardive dyskinesia (TD) related differentially to two types of cognitive functioning in schizophrenia. Thirteen schizophrenics with severe formal thought disorders (+FTD) were matched for age, sex, education, chronicity, dosage, hospital care, with 13 schizophrenics selected for absence of or minimal formal thought disorders (-FTD). TD and neuroleptic dosage were analyzed in relation to cognitive and motor tests of the Luria-Nebraska (L-N) battery and to attentional evoked potentials (EPs). EPs were recorded at electrodes Fz, Cz, and Pz, in a dichotic signal detection task (oddball paradigm), during attention and inattention conditions. Group differences on attentional EPs replicated published results with flatter and smaller positive waves in +FTD patients and larger late negative waves (FzN4-N7) in -FTD patients. Controlling for dosage, the following were the best groups discriminators. +FTD schizophrenics presented more severe dyskinesia in the orofacial area and poorer verbal scores on L-N. Severe TD correlated with smaller N1 amplitudes. +FTDs also presented distinct attentional EP deficits with abnormally small P3a, a correlate of deficient categorization and orienting. Neuroleptic dosage was not directly correlated to any single motor or cognitive measure, nor to TD indices. The hypothesis of a differential association of TD with distinct attentional/cognitive disorders was generally supported.
authors.affiliation: Concordia University, Department of Psychology, Montréal, Canada.
authors.forename: J
authors.initials: J
authors.lastname: Baribeau
authors.forename: J P
authors.initials: JP
authors.lastname: Laurent
authors.forename: A
authors.initials: A
authors.lastname: Décary
mesh_terms: D000161:Acoustic Stimulation; D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000145:classification / Q000627:therapeutic use; D003072:Cognition Disorders / Q000150:complications* / Q000175:diagnosis / Q000503:physiopathology; D004409:Dyskinesia, Drug-Induced / Q000150:complications* / Q000175:diagnosis / Q000503:physiopathology; D005072:Evoked Potentials, Auditory; D005260:Female; D006801:Humans; D008182:Luria-Nebraska Neuropsychological Battery; D008297:Male; D011597:Psychomotor Performance / Q000187:drug effects; D012559:Schizophrenia / Q000188:drug therapy
chemical_list: D014150:Antipsychotic Agents